BMRN
Income statement / Annual
Last year (2024), BioMarin Pharmaceutical Inc.'s total revenue was $2.85 B,
an increase of 17.97% from the previous year.
In 2024, BioMarin Pharmaceutical Inc.'s net income was $426.86 M.
See BioMarin Pharmaceutical Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
Operating Revenue |
$2.85 B |
$2.42 B |
$2.10 B |
$1.85 B |
$1.86 B |
$1.70 B |
$1.49 B |
$1.31 B |
$1.12 B |
$889.90 M |
Cost of Revenue |
$580.24 M
|
$577.07 M
|
$483.67 M
|
$470.52 M
|
$524.27 M
|
$359.47 M
|
$315.26 M
|
$241.79 M
|
$209.62 M
|
$152.01 M
|
Gross Profit |
$2.27 B
|
$1.84 B
|
$1.61 B
|
$1.38 B
|
$1.34 B
|
$1.34 B
|
$1.18 B
|
$1.07 B
|
$907.23 M
|
$737.89 M
|
Gross Profit Ratio |
0.8
|
0.76
|
0.77
|
0.75
|
0.72
|
0.79
|
0.79
|
0.82
|
0.81
|
0.83
|
Research and Development Expenses |
$747.18 M
|
$746.77 M
|
$649.61 M
|
$628.79 M
|
$628.12 M
|
$715.01 M
|
$696.33 M
|
$610.75 M
|
$661.91 M
|
$634.81 M
|
General & Administrative Expenses |
$0.00
|
$448.90 M
|
$403.71 M
|
$354.30 M
|
$334.30 M
|
$0.00
|
$604.35 M
|
$554.34 M
|
$476.59 M
|
$402.27 M
|
Selling & Marketing Expenses |
$0.00
|
$488.40 M
|
$450.30 M
|
$405.10 M
|
$403.40 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$1.01 B
|
$937.30 M
|
$854.01 M
|
$759.38 M
|
$737.67 M
|
$680.92 M
|
$604.35 M
|
$554.34 M
|
$476.59 M
|
$402.27 M
|
Other Expenses |
$33.26 M
|
$0.00
|
$67.19 M
|
$69.93 M
|
$66.66 M
|
$74.11 M
|
$2.21 M
|
$7.97 M
|
$4.93 M
|
-$9.30 M
|
Operating Expenses |
$1.79 B
|
$1.75 B
|
$1.57 B
|
$1.46 B
|
$1.43 B
|
$1.47 B
|
$1.35 B
|
$1.21 B
|
$1.11 B
|
$1.02 B
|
Cost And Expenses |
$2.37 B
|
$2.27 B
|
$2.05 B
|
$1.93 B
|
$1.96 B
|
$1.83 B
|
$1.66 B
|
$1.45 B
|
$1.32 B
|
$1.17 B
|
Interest Income |
$74.88 M
|
$58.34 M
|
$18.03 M
|
$10.48 M
|
$16.61 M
|
$22.75 M
|
$22.83 M
|
$14.85 M
|
$7.49 M
|
$4.50 M
|
Interest Expense |
-$12.67 M
|
$17.34 M
|
$15.97 M
|
$15.34 M
|
$29.31 M
|
$23.46 M
|
$43.66 M
|
$42.71 M
|
$39.50 M
|
$38.24 M
|
Depreciation & Amortization |
$0.00
|
$104.39 M
|
$101.97 M
|
$108.04 M
|
$105.88 M
|
$105.30 M
|
$95.50 M
|
$87.92 M
|
$86.03 M
|
-$17.69 M
|
EBITDA |
$484.21 M |
$310.28 M |
$267.52 M |
$48.03 M |
-$5.85 M |
$33.95 M |
-$3.54 M |
$94.76 M |
-$705.53 M |
-$110.70 M |
EBITDA Ratio |
0.17
|
0.13
|
0.08
|
0.03
|
-0
|
-0.01
|
-0.07
|
-0.05
|
-0.17
|
-0.32
|
Operating Income Ratio |
0.17
|
0.08
|
0.03
|
-0.03
|
-0.05
|
-0.07
|
-0.08
|
-0.01
|
-0.72
|
-0.12
|
Total Other Income/Expenses Net |
$57.55 M
|
-$5.88 M
|
$14,000.00
|
-$15.34 M
|
-$5.56 M
|
$5.65 M
|
-$19.18 M
|
-$35.86 M
|
-$27.62 M
|
-$44.02 M
|
Income Before Tax |
$541.76 M
|
$188.56 M
|
$149.58 M
|
-$75.35 M
|
-$42.32 M
|
-$94.81 M
|
-$142.71 M
|
-$35.88 M
|
-$831.05 M
|
-$154.72 M
|
Income Before Tax Ratio |
0.19
|
0.08
|
0.07
|
-0.04
|
-0.02
|
-0.06
|
-0.1
|
-0.03
|
-0.74
|
-0.17
|
Income Tax Expense |
$114.90 M
|
$20.92 M
|
$8.02 M
|
-$11.27 M
|
-$901.42 M
|
-$70.96 M
|
-$65.49 M
|
$81.17 M
|
-$200.84 M
|
$17.08 M
|
Net Income |
$426.86 M
|
$167.65 M
|
$141.56 M
|
-$64.08 M
|
$854.03 M
|
-$23.85 M
|
-$77.21 M
|
-$117.04 M
|
-$630.21 M
|
-$171.80 M
|
Net Income Ratio |
0.15
|
0.07
|
0.07
|
-0.03
|
0.46
|
-0.01
|
-0.05
|
-0.09
|
-0.56
|
-0.19
|
EPS |
2.25 |
0.89 |
0.76 |
-0.35 |
4.75 |
-0.13 |
-0.44 |
-0.67 |
-3.8 |
-1.07 |
EPS Diluted |
2.17 |
0.87 |
0.75 |
-0.35 |
4.53 |
-0.13 |
-0.44 |
-0.67 |
-3.79 |
-1.07 |
Weighted Average Shares Out |
$190.03 M
|
$187.83 M
|
$185.27 M
|
$182.85 M
|
$180.80 M
|
$179.04 M
|
$177.06 M
|
$174.43 M
|
$165.99 M
|
$160.03 M
|
Weighted Average Shares Out Diluted |
$196.71 M
|
$191.60 M
|
$188.96 M
|
$182.85 M
|
$191.68 M
|
$179.04 M
|
$177.27 M
|
$174.43 M
|
$166.22 M
|
$160.03 M
|
Link |
|
|
|
|
|
|
|
|
|
|